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AbstrACt
Objectives To determine the potential costs and health 
benefits of a serum-based spectroscopic triage tool 
for brain tumours, which could be developed to reduce 
diagnostic delays in the current clinical pathway.
Design A model-based health pre-trial economic 
assessment. Decision tree models were constructed based 
on simplified diagnostic pathways. Models were populated 
with parameters identified from rapid reviews of the 
literature and clinical expert opinion.
setting Explored as a test in both primary and secondary 
care (neuroimaging) in the UK health service, as well as 
application to the USA.
Participants Calculations based on an initial cohort of 
10 000 patients. In primary care, it is estimated that the 
volume of tests would approach 75 000 per annum. The 
volume of tests in secondary care is estimated at 53 000 
per annum.
Main outcome measures The primary outcome measure 
was quality-adjusted life-years (QALY), which were 
employed to derive incremental cost-effectiveness ratios 
(ICER) in a cost-effectiveness analysis.
results Results indicate that using a blood-based 
spectroscopic test in both scenarios has the potential to 
be highly cost-effective in a health technology assessment 
agency decision-making process, as ICERs were well 
below standard threshold values of £20 000–£30 000 per 
QALY. This test may be cost-effective in both scenarios 
with test sensitivities and specificities as low as 80%; 
however, the price of the test would need to be lower (less 
than approximately £40).
Conclusion Use of this test as triage tool in primary care 
has the potential to be both more effective and cost saving 
for the health service. In secondary care, this test would 
also be deemed more effective than the current diagnostic 
pathway.
IntrODuCtIOn 
At an average of 20 years, patients with malig-
nant brain tumours have the highest number 
of years of life lost, compared with all other 
primary cancers.1 This, at least in part, may 
relate to diagnostic delays, reflecting the 
non-specific early symptoms, such as head-
ache and dizziness, from which general 
practitioners (GP) must identify patients at 
risk for further investigation. The lack of a 
low-cost diagnostic and/or screening tools 
available within the health service contributes 
to this delay. We have recently demonstrated 
that a spectroscopic test using blood serum is 
able to effectively identify brain tumours in 
patients with sensitivities and specificities as 
high as 92.8% and 91.5%, respectively, in a 
strengths and limitations of this study
 ► Simplified models of clinical pathways were mapped 
with input from, and consensus among, a wide 
range of clinical experts including neurosurgeons, 
neuro-oncologists, neuropathologists, neuroradiolo-
gists and primary care experts.
 ► The spectroscopic blood test was highly sensitive 
and specific in retrospective data, with performances 
of 92.8% and 91.5%, respectively. There is potential 
for this to contribute towards improved prognosis for 
patients, as well as healthcare savings.
 ► This study is based on proof-of-concept studies, in 
advance of a pending prospective clinical trial. As 
these samples are retrospective, there is the possi-
bility the diagnostic performance will not be as high 
in prospective studies.
 ► A lack of clinical trial evidence necessitates the es-
timate of long-term benefits of improved diagnostic 
protocols based on disease natural history models. 
This creates additional uncertainties.
 ► The precise patient population for whom the test 
may be suitable in the primary care setting is dif-
ficult to establish at this stage in development. This 
study considers a limited definition of eligibility that 
may need revision in light of future evidence.
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tissue bank case–control series.2 3 This approach is based 
on Fourier-transform infrared (FTIR) spectroscopy and 
can detect disease-specific signatures, which are extracted 
mathematically using pattern recognition and machine 
learning algorithms.
Current diagnostic pathway
Currently, patients who are symptomatic with a brain 
tumour visit their GP on average five times before being 
referred to secondary care.4 Partly as a result of this diag-
nostic delay, up to 61% of brain tumour diagnoses occur in 
an emergency setting, often following a seizure.5 Patients 
diagnosed by the emergency route have a poorer prog-
nosis.6 7 For some patients this may be because the disease 
is at a more advanced stage at diagnosis. The complica-
tions precipitating the emergency admission make an 
additional contribution to mortality.
Screening programmes for breast, prostate, cervical and 
colorectal cancers have proved effective for diagnosing 
patients at an earlier stage, which can result in a better 
prognosis.8–11 These screening programmes have had a 
significant impact in reducing the number of patients 
presenting as an emergency. To date there has been no 
accessible and economically viable diagnostic tool for 
early detection of asymptomatic and symptomatic brain 
tumours.12 The addition of a rapid and accurate blood 
test for patients with suspected primary brain tumours 
(symptomatic patients) therefore has the potential to 
improve outcomes by allowing prioritisation of patients 
most at risk of a brain tumour for further investigation. 
Under the current patient pathway it is not feasible to 
provide fast-track diagnostic imaging because the number 
of patients with non-specific headache symptoms is very 
large and the positive predictive value (PPV) on the basis 
of symptoms alone is less than 3% for all symptoms other 
than a new-onset seizure.13 14
MRI and CT are the current gold standard for iden-
tifying structural brain lesions including tumours. 
Treatment decisions made at the neuro-oncology multi-
disciplinary team meeting are often based on the imaging 
alone. Following surgical resection or biopsy with histopa-
thology and molecular analysis, definitive treatment can 
be planned.15 Surgery to secure the tissue diagnosis has 
a small risk to the patient of neurological deterioration 
and death.16
The diagnostic pathway also represents a significant 
cost burden to the health service, with a single MRI and 
CT scan in the UK costing around £164 and £85, respec-
tively (National Schedule of Reference Costs (2014–
2015), Medicare Physician Fee Schedule 2016). A typical 
timeframe of the diagnostic pathway for brain tumours, 
specifically primary gliomas, is illustrated in figure 1, and 
effectively highlights the significant wait that a symptom-
atic patient may have before receiving brain imaging. 
Even from this stage, regardless of the time to GP referral 
or emergency presentation, full diagnosis may take a 
further 5 weeks.
serum spectroscopic diagnostics
This novel blood test for early brain tumour detection is 
based on the interaction of infrared (IR) light with biolog-
ical components of blood serum (figure 2). Specifically, 
using attenuated total reflectance (ATR)-FTIR spectros-
copy, specific bond vibrations of given molecules can be 
elucidated from serum samples, thus providing a unique 
insight into the composition via an absorbance spec-
trum.17 Benefits of an ATR-FTIR-based approach include 
a robust, user-friendly methodology without extensive 
sample preparation, which would readily fit into a clin-
ical setting.18 In short, serum is obtained according to 
standard protocols and can be snap frozen and stored at 
−80° until the point of analysis. A small volume of serum 
is required for analysis (1–5 µL), which is pipetted onto a 
crystal, known as an internal reflection element, where IR 
non-destructively interacts with the sample and produces 
an IR spectrum, with peaks representative of known bond 
vibrations and hence biomolecular constituents.
Blood serum is a complex medium that contains a 
variety of biomolecules, including around 20 000 proteins, 
which may be employed as diagnostic biomarkers.19 In 
the case of brain tumours, such blood-based technol-
ogies are limited, due to a lack of an established brain 
tumour-specific diagnostic biomarker.20 With our spectro-
scopic approach, rather than derive single biomarker-spe-
cific information, a global signature is obtained which 
encompasses the entire biomolecular makeup. This is 
epitomised as an equally complex biological absorbance 
spectrum, which contains a wealth of diagnostic informa-
tion (an example may be seen in figure 3).
Figure 1 The diagnostic pathway of brain tumours. Timings 
relate to the diagnosis of high-grade gliomas and are based 
on discussion with the Clinical Focus Team and Aggarwal 
et al.5 GP, general practitioner; MDT, multidisciplinary team; 
OPD, outpatient department. 
Figure 2 Attenuated total reflectance Fourier-transform 
infrared (ATR-FTIR) spectroscopic test of blood serum for the 
diagnosis and stratification of brain tumours using machine 
learning algorithms.
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Pattern recognition and machine learning algorithms 
using spectral features from FTIR data have been demon-
strated as rapid and accurate for separating primary brain 
cancer and non-cancer cases.2 21 When these algorithms 
are applied to this information rich data set, the relation-
ship between all biological components of the sample is 
ascertained, providing a multidimensional analysis of the 
sample.
In the case–control setting, this approach has been able 
to detect between cancer and non-cancer, and stratify 
based on cancer pathology.2 For further information and 
in-depth description of the methodology, we direct the 
readers to the following fundamental review and recent 
research papers.2 3 17 21 The ability to triage patients 
likely to have a brain tumour based on serum sample 
alone raises the possibility of systematic triaging prior to 
investigation with more expensive (MRI/CT imaging) 
and invasive (biopsy) tests. One major impact of having 
a serum test available would be a possible reduction in 
the number of unnecessary brain scans; however, as this 
test is also able to differentiate between primary and 
secondary tumours, there could also be a knock-on reduc-
tion of chest and abdomen scans which are conducted 
to rule out primary disease elsewhere. There is also the 
possibility that this approach will reduce the incidence of 
incidental abnormalities which in themselves can cause 
considerable distress. Ultimately, it is expected that this 
could allow earlier and potentially more effective treat-
ment of brain tumours.
It is important to note that this study is based on proof-
of-concept studies, in advance of a pending clinical trial. 
As these samples are retrospective, there is the possi-
bility the diagnostic performance will not be as high in 
prospective studies. In addition to determining the true 
diagnostic accuracy of the technique, the planned clin-
ical trial held in primary care will also reveal the suitable 
patient population for the test, as well as the long-term 
benefits of an improved diagnostic pathway.
Aims and objectives
The aim of the economic evaluation is to assess the poten-
tial cost-effectiveness of this spectroscopic technology, in 
advance of any prospective study results being available. 
There are three main objectives for the evaluation; first 
to create a map of where the test could be used in the 
clinical pathway. The second is to assess the potential 
cost-effectiveness of the technology, if the performance 
shown in the case–control study is replicated prospec-
tively. This will give an indication of whether the tech-
nology would meet the criteria for acceptance for use in 
the National Health Service (NHS) that are applied by 
health technology assessment (HTA) agencies. Related 
to this, the third objective is to define the level of perfor-
mance in prospective trials, and any additional evidence 
that would be needed to meet the cost-effectiveness 
criteria of an HTA decision-making process. This can 
include diagnostic performance and also effects on 
long-term outcomes such as survival and resource use. 
To achieve these objectives a simplified economic model 
of two important clinical scenarios is used to explore 
cost-effectiveness.
MethODOlOgy
Mapping the clinical pathway
In order to appreciate the current clinical pathway and 
determine an appropriate entry point for a serum spec-
troscopic test, a pan-UK clinical focus group was estab-
lished. This cohort included neurosurgeons, clinical and 
medical oncologists, neuropathologists, neuroradiolo-
gists, academic GPs with special interests and experts 
in primary care diagnostics (see online supplementary 
appendix 1).
Cost-effectiveness analysis
A cost-effectiveness analysis was conducted to calculate 
the effects on health outcomes and health service costs of 
introducing spectroscopic testing in each of two scenarios. 
The health outcomes considered were life-years and qual-
ity-adjusted life-years (QALY).
A decision tree was used to model the pathway for 
patients presenting with symptoms warranting a referral 
for MRI/CT imaging for suspected brain tumour 
(figure 4). Separate models were considered for primary 
and secondary care. The time horizon of the model is 2 
years and the perspective is that of the healthcare service. 
A 2-year horizon was selected because of the short dura-
tion of survival in this patient group: median survival is 
approximately 1 year for high-grade gliomas, which are 
the most common malignant primary brain tumour. In 
all scenarios the comparator is the current diagnostic 
pathway (ie, imaging alone). Further details regarding 
the node probabilities, simplifications and assumptions 
of the model can be found in online supplementary 
appendix 2.
Figure 3 An unprocessed spectrum derived from human 
blood serum using attenuated total reflectance Fourier-
transform infrared (ATR-FTIR) spectroscopy. Spectral regions 
correspond to known bond vibrations and can therefore be 
associated with groups of biomolecules such as protein, lipid, 
phosphate and carbohydrates. Broad examples of blood 
serum constituents are listed.
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Diagnostic performance
The sensitivity and specificity of the test for detecting 
brain tumours has been demonstrated in a series of 
case–control studies using historical samples from the 
Brain Tumour North West and Walton Centre NHS 
biobanks.2 3 In the key case–control study nine FTIR 
spectra were collected from each of 433 patients.3 
Of these, 134 were from patients with primary brain 
tumours (64 high-grade glioma), 177 were from patients 
with cerebral metastases and 122 were from non-cancer 
controls. FTIR spectra were analysed using the random 
forest method to fit a classification model. Classification 
performance was estimated by applying the fitted model 
to a test set containing 20% of the patients from the orig-
inal data set that were not used in the model fitting step 
(hold-out test set). Classification statistics are computed 
as averages of this process, iterated 96 times using 
random training and test sets. Under the best available 
model, sensitivity estimated by this method was 92.8% 
and specificity was 91.5% for the analysis of cancerous 
versus non-cancerous serum.3 These classification statis-
tics were established using 96 independent iterations of 
a random forest model, and resulted in SDs of 1.1% and 
1.9%, respectively.
Establishing whether the performance demonstrated 
case–control data from historical samples translates to 
equivalent performance when applied prospectively in 
clinical practice is the subject of a planned clinical trial. 
This is critical to demonstrating the clinical and cost-ef-
fectiveness of a serum spectroscopy test as part of the 
diagnostic pathway for brain tumours.
Prevalence of disease
Prevalence data were sourced from the literature based 
on clinical expert guidance. Brain tumour prevalence in 
scenario 2 (secondary care) was assumed to be 3% based 
on observed rates of primary brain tumour diagnosis 
among patients referred for brain imaging for suspected 
cancer in secondary care.22–24 In scenario 1 (primary 
care) an estimated prevalence of 0.5% is used based on 
case–control evidence and expert opinion of the preva-
lence among patients who would be considered for direct 
access imaging, using MRI or CT, where this is available 
and referral to neurology where it is not.25 26 An alterna-
tive prevalence of 1% was explored for scenario 1 based 
on unpublished data from a direct access imaging service 
in the UK (P Brennan, personal communication).
The effect of serum spectroscopy testing on the 
time to diagnosis and time to treatment is discussed in 
online supplementary appendix 3, in addition to the 
effect of testing on the use of imaging studies, and also 
on the patient outcomes. The primary assumptions in 
this model are that first, the expected time to diagnosis 
would match the current median time to diagnosis for 
patients presenting with brain tumour in emergency care 
as observed in Aggarwal et al’s study.5 Furthermore, based 
on expert opinion, it is assumed that in secondary care 
all patients would continue to imaging, while in primary 
care 50% would continue to imaging following a nega-
tive spectroscopy result. This is a conservative estimate 
associated with the possibility that an imaging test will still 
be required in some cases based on interpretation of a 
patient’s symptoms and the other non-tumour diagnoses 
being considered by the clinician. Finally, the effects of 
early diagnosis on the outcome of brain tumours are esti-
mated using literature describing fitting natural history 
models to observational data sets of patients with high-
grade glioma.1 27
utility weights
Health state utility weights are applied to life-years to 
generate QALYs. A systematic review of health state utility 
weights for high-grade glioma, the most common and 
aggressive primary brain tumour, was conducted to iden-
tify suitable utility weights. Due to heterogeneity it was 
not considered suitable to pool the estimates. The most 
appropriate health state utility weight was taken from a 
previous UK economic evaluation of glioblastoma treat-
ment.28 A value of 0.89 was used in the base case.
resource use and costs
Resource use includes the application of a spectroscopic 
serum test to all patients prior to imaging, the imaging 
studies used in the diagnostic process, outpatient 
neurology clinic visits and GP visits. In the UK analysis, 
unit costs for imaging studies are taken from UK NHS 
reference costs (2014/2015), clinic and GP visits from 
the Personal Social Services Research Unit (PSSRU) costs 
schedule (table 1). In the US analysis, unit costs are taken 
from Medicare reimbursement schedules. Unit costs of 
Figure 4 A decision tree model describing the integration of 
a serum spectroscopy test in the current diagnostic pathway, 
and the effect on MRI/CT imaging for suspected brain 
tumour. D1, 1 week; D2, 4 weeks; D3, 8 weeks; LY, life-year; 
S(t|D), survival time in days conditional on ‘delay’. 
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the test were applied at an upper bound and lower bound 
rather than a single value as these products have not yet 
been commercialised. Bounds were set by consultation 
with scientists developing the tests. Additional resource 
use and cost assumptions are described in online supple-
mentary appendix 3.
Incremental cost-effectiveness ratios
The comparative cost-effectiveness of spectroscopic 
testing compared with no testing is summarised by the 
incremental cost-effectiveness ratio (ICER) defined as:
  
ICER =
Cs − Cn
Hs −Hn   
 Cs   and  Cn  are the total costs with spectroscopic testing 
and no testing, respectively. Equivalently,  Hs   and  Hn  are 
the total QALYs with and without spectroscopic testing. 
The ICER can be interpreted as the additional cost per 
QALY gained.
base case and sensitivity analysis
ICERs were calculated for scenarios 1 and 2 using the base 
case parameter estimates. Base case analysis was repeated 
for UK and USA settings. Additional sensitivity analyses 
are reported for the UK setting only.
Sensitivity analyses included one-way sensitivity anal-
ysis (OWSA), systematically varying a single parameter in 
the model, and scenario analysis in which specific model 
assumptions were altered. OWSA was conducted for test 
sensitivity, specificity and test cost. Scenario analyses 
included assuming an additional consultation cost for 
discussion of test results, assuming a higher proportion 
of patients continue to imaging following a negative spec-
troscopy result in primary care and using mean survival 
rather than median survival.
A probabilistic sensitivity analysis (PSA) was conducted 
to explore the effects of joint uncertainty in the param-
eter estimates on the model results.29
Patient and public involvement
Patients and the public were not actively involved in the 
formation of this study. The impact of the test on clin-
ical decision-making was the priority in this instance; 
however, the involvement of patients going forward will 
be fundamental to understanding the tests uptake into 
the health services.
results
Mapping the clinical pathway
For the first study objective, initial discussion with clin-
ical experts indicated that there are potential uses for 
the test in both primary and secondary care. The main 
advantage of employing a cost-effective spectroscopic 
blood test in the diagnostic pathway is to use it as a 
triage test. This prioritises more urgent cases for access 
to services, and acts as a gatekeeper (requiring a positive 
result in some conditions to give access to services) for 
imaging studies.
Two clinical scenarios are mapped out below and subse-
quently explored in this early economic evaluation of 
the serum spectroscopy test for aiding diagnosis of brain 
tumours.
Triage tool in primary care
The primary care scenario explores a population of 
patients with a clinical presentation that warrants further 
investigation of possible brain tumour. This would 
include some patients with headaches and some with 
focal neurological deficits. This is the group of patients 
who would be considered for direct access imaging, 
using MRI or CT, where this is available and referral to 
neurology where it is not.30 The blood test is used to 
provide rapid information, within 24 hours, where a posi-
tive result would lead to patients receiving more timely 
access to imaging. It may also be the case that negative 
test results, in addition to establishing the low probability 
of a brain tumour, could also provide some reassurance 
for those patients who must wait for imaging. The total 
volume of tests would be approximately 75 000 per year in 
the UK (see online supplementary appendix 4 for further 
details).
Table 1 Unit costs and comparison for the brain tumour 
diagnostic pathway
Item
UK cost 
per unit 
(£) (2015 
prices)
USA cost 
per unit 
($) (2016 
prices) Source(s)
CT imaging 
study
(CT head)
85 163 National Schedule 
of Reference Costs 
(2014–2015), 
Medicare Physician 
Fee Schedule (2016)
MRI imaging 
study
(MRI brain 
with contrast)
164 380 National Schedule 
of Reference Costs 
(2014–2015), 
Medicare Physician 
Fee Schedule (2016)
Neurology 
outpatient 
appointment
35 76 PSSRU (2016), 
Medicare Physician 
Fee Schedule (2016)
GP visit 47.25 76 PSSRU (2016), 
Medicare Physician 
Fee Schedule (2016)
Stable 
disease 
monitoring 
costs
116 per 
3 months
154 28, exchange rate 
adjusted
Serum 
spectroscopy 
test
Lower 
limit: 50
Upper 
limit: 100
Lower 
limit: 100
Upper 
limit: 200
Assumed prices
GP, general practitioner; PSSRU, Personal Social Services 
Research Unit. 
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Triage tool in secondary care
In this scenario the population is the group of patients who 
are currently referred for imaging studies from secondary 
care for suspected brain tumour, typically via neurology 
clinics. This is the patient group for whom the clinical 
presentation has the highest PPV. However, even in this 
high-risk group, the odds of a brain tumour being present 
are approximately 1:33.22–24 Again, the spectroscopy test 
is used to provide rapid information to allow a subset of 
these patients to access immediate imaging and provide 
reassurance to other patients who may have to wait longer 
for definitive imaging studies and diagnosis. The extent 
of the benefits of triage in this scenario is likely to vary by 
locality depending on the capacity constraints on imaging 
and pathology services. This evaluation uses estimates of 
the delays in diagnosis, and potential improvements in 
the speed of diagnosis, from a consecutive patient case 
series in London, UK.5 The total volume of tests if this 
scenario occurred would be approximately 53 000 per 
year in the UK (see online supplementary appendix 4 for 
further details).
Cost-effectiveness assessment
The standard threshold value per QALY gained in the UK 
is considered to be between £20 000 and £30 000. Below 
this value, a healthcare intervention may be considered 
cost-effective, whereas a negative ICER value would 
be deemed cost saving. Base case results for primary 
care (scenario 1) and secondary care (scenario 2) are 
presented in table 2. Note results are reported for cohorts 
of 10 000 patients.
ICERs were well below standard threshold values of 
£20 000–£30 000 per QALY gained used in the UK, and 
similar thresholds used internationally, provided the test 
cost did not exceed £100. The base case results demon-
strate that the serum spectroscopy test dominates (more 
effective and less costly) standard care at the lower bound 
of test cost in the primary care setting in both the UK 
and USA. At the upper bound of test cost the ICERs 
may be within commonly used thresholds or, in the case 
of the USA, remain dominant to standard care. In the 
secondary care setting ICERs of £9982 and $10 153 at the 
lower bounds of test cost indicate that this test is poten-
tially cost-effective in this setting. At the upper bounds 
ICERs may still be within commonly used thresholds for 
cost-effectiveness.
sensitivity analysis results
The performance of the test with regard to levels of sensi-
tivity and specificity is addressed using sensitivity analysis. 
OWSA results for a range of test specificities are displayed 
in figures 5 and 6, for primary and secondary care, respec-
tively, displaying the ICER with varying test specificity. 
Note that the estimated QALYs do not change with speci-
ficity in the model, therefore changes in the ICER are due 
solely to changes in incremental costs. Varying sensitivity 
changes both estimated QALYs and estimated costs there-
fore results of the OWSA for test sensitivity are presented 
on the cost-effectiveness plane (online supplementary 
appendix 5). In primary care, using the upper cost limit 
of £100 it is evident that the test is deemed cost-effective 
at specificities of around 0.9 and above, where the ICER 
Figure 5 Incremental cost-effectiveness ratios (ICER) at 
various specificities in primary care (‘Scenario 1’). The £30 
000 ICER threshold is displayed as a dashed horizontal 
line. QALY, quality-adjusted life-year. 
Table 2 Incremental QALYs, costs and ICERs for scenarios 1 and 2, UK and USA
Serum 
spectroscopy 
test cost (£)
Scenario 1—primary care Scenario 2—secondary care
∆QALY ∆Cost ICER ∆QALY ∆Cost ICER
UK
  50 8.81 −422 116 −47 913
(dominates)
52.86 527 646 9982
  100 8.81 77 884 8840 52.86 1 027 646 19 441
USA
  100 8.81 −1 718 475 −195 058 
(dominates)
52.86 536 702 10 153
  200 8.81 −218 475 −24 798
(dominates)
52.86 2 036 702 38 530
∆QALY, ∆Cost: difference is QALYs/costs (with serum spectroscopy test—without test), 10 000 patients.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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is below standard thresholds. In contrast, at the lower cost 
limit, the test is cost-effective at specificities above 0.8. 
Although the serum spectroscopy test is not cost saving 
at low cost (or near perfect specificities), the test is still 
considered cost-effective at specificity levels around 0.7 
and 0.8 for £50 and £100 pricing, respectively.
The OWSA results highlight how ICERs in scenario 2 
(secondary care) are strongly influenced by test sensi-
tivity while ICERs in scenario 1 (primary care) are more 
strongly influenced by test specificity. These features are a 
result of the varying prevalence of disease and the assump-
tion in scenario 2 that 100% of patients are referred for 
imaging following negative result. It should be noted that 
test specificity is important in both scenarios. Relatively 
small improvements in test specificity can substantially 
change the ICER, while larger improvements in test sensi-
tivity are required to substantially alter the ICERs.
Additional scenario analyses are also reported in online 
supplementary appendix 5. These demonstrate that 
results are robust to using mean survival estimates rather 
than median survival estimates and including additional 
consultation costs for positive test results. If the preva-
lence of brain tumours in scenario 1 is 1% rather than 
0.5% the incremental QALYs increase substantially and 
the ICERs are reduced.
The PSA results reported in figures 7 and 8 indicate that 
at a test cost of £50 and an ICER threshold of £30 000 per 
QALY there is a near 100% probability the serum spec-
troscopy test is cost-effective in scenario 1 and approxi-
mately 90% probability it is cost-effective in scenario 2. 
The corresponding probabilities at the upper bound cost 
of £100 are approximately 85% and 75%.
DIsCussIOn
This economic evaluation establishes the potential for 
serum spectroscopy to have a role in the diagnosis of both 
benign and malignant brain tumours in both primary and 
secondary care. The potential costs and health benefits of 
testing using a spectroscopic method prior to CT/MRI 
tests (or in some scenarios to avoid imaging) have been 
estimated based on a mathematical model with param-
eter values taken from published studies and expert 
opinion. This diagnostic tool is sensitive to all brain 
tumours (benign or malignant); however, this assessment 
is closely aligned with the diagnosis of primary gliomas, 
where there is a maximum potential benefit to the health 
service.
The major limitations of this analysis relate to the 
use of proof-of-concept studies and a disease natural 
history model rather than direct clinical trial evidence. 
This creates additional uncertainties. Results should be 
interpreted as indicative and used primarily to guide 
future evidence generation. Furthermore, the scenarios 
explored were limited in scope; future studies should 
continue to refine understanding of the role of the test in 
real-world clinical decision-making.
When used as a triage tool in primary care, this novel 
test has the potential to deliver improvements in health 
outcomes and also to reduce costs. At the lower end of 
test costs, the technology would be cost-saving for the 
health service. At higher test costs the technology is still 
Figure 6 Incremental cost-effectiveness ratios (ICER) 
at various specificities in secondary care (‘Scenario 2’). The 
£30 000 ICER threshold is displayed as a dashed horizontal 
line. QALY, quality-adjusted life-year. 
Figure 7 Cost-effectiveness acceptability curve (CEAC) at 
£50 and £100 per test—primary care (‘Scenario 1’). QALY, 
quality-adjusted life-year. 
Figure 8 Cost-effectiveness acceptability curve (CEAC) at 
£50 and £100 per test—secondary care (‘Scenario 2’). QALY, 
quality-adjusted life-year. 
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likely to be considered cost-effective in HTA agency deci-
sion processes.
In scenario 2, in which serum spectroscopy is used as a 
triage tool in secondary care, the technology will create 
additional costs and also produce sizeable health bene-
fits. At test costs of under £100 ($200) the technology 
would be likely to be considered as a cost-effective use 
of resources in HTA agency decision processes in the 
UK (and USA). It is assumed that in both scenarios, the 
uptake of the test in the USA would mirror that of the 
UK; however, this would need to be explored further, 
alongside clinical experts of the USA care pathways.
Sensitivity analyses have demonstrated the importance 
of diagnostic performance on the cost-effectiveness of 
the test. In particular, test specificity is important in the 
primary care setting. If test specificity is 87.5% or worse, 
the technology may not be considered cost-effective 
at higher values of assumed test cost. This is due to the 
increased number of false positive results in this low prev-
alence population, generating a greatly increased propor-
tion of fast-track imaging studies which increases costs.
To strengthen the case that this approach represents a 
cost-effective use of healthcare resources it is necessary to 
establish the diagnostic performance of the test prospec-
tively. This can be accomplished by a suitably large cohort 
study in which serum spectroscopy is used alongside 
current clinical practice in one of the patient groups 
included in this evaluation. It would be appropriate to 
initially target the secondary care patient population, 
because the higher prevalence of disease in this group 
will reduce the sample size needed to accurately estimate 
diagnostic performance.
Decision makers are often most interested in patient 
outcomes, such as survival, rather than intermediate 
outcomes, such as accuracy or speed of diagnosis 
(although this latter point is vital for treatment of high-
grade gliomas). From this perspective, a randomised trial, 
or a prospective cohort study with extended follow-up, 
may be required to fully establish the size of survival and 
quality-of-life benefits of including a serum spectros-
copy test in the diagnostic pathway. A trial with primary 
outcomes relating to survival and quality of life would be 
specific to either the primary or secondary care setting 
(rather than generalisable to both), would need a large 
sample size and would also require a follow-up period to 
capture survival benefits. In the case of malignant glioma 
this would require a period of at least 24 months. Such a 
trial would clearly be expensive, time consuming and may 
be unfeasible. Decision makers may be willing to make a 
decision on implementation of the blood test based on 
the modelled effects of improvements in intermediate 
outcomes on later patient outcomes. In this situation, the 
model proposed in this evaluation, populated with diag-
nostic performance and other data from a prospective 
trial, could be used to inform decisions about the wider 
adoption of the technology.
Future developments beyond trials such as emerging 
epidemiological evidence and new technologies should 
also be included in any future evaluations. It was not 
possible to foresee and include all such possible scenarios 
in this early evaluation but that should not preclude 
assessment in the light of new evidence. Updated anal-
ysis should inform any decisions about system-wide 
implementation.
Several results in this analysis suggest cost savings 
through reduced use of imaging for patients with a nega-
tive test result. To make the case that a serum spectro-
scopic test can improve the efficiency of the diagnostic 
pathway prospective studies will also need to explore 
the impact of these test results on clinician and patient 
imaging study decisions. The possibility remains that the 
test may triage patients, but may not reduce the number 
of scans being conducted, and could potentially increase 
the demand on imaging. For example, if the test is applied 
to a wider population than intended in primary care due 
to the availability of such a non-invasive test effectively 
lowering the threshold for investigation. This highlights 
the need to study decision-making in this area prior to 
any implementation in primary care. Nevertheless, this 
triaging of patients would still benefit each patient who is 
provided with an early diagnosis.
This evaluation has explored the potential for serum 
spectroscopy to be a cost-effective addition to the diag-
nostic pathway for brain tumours. It has demonstrated 
that in specific scenarios this novel test may be an effec-
tive and cost-effective technology in reducing the delay 
to diagnosis for patients with brain tumours. Prospective 
trials are required to provide definitive evidence.
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